Prognostic Scoring Systems in CML - Improvement Impossible?

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F15%3A33155103" target="_blank" >RIV/61989592:15110/15:33155103 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.4172/2329-6917.S1-001" target="_blank" >http://dx.doi.org/10.4172/2329-6917.S1-001</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.4172/2329-6917.S1-001" target="_blank" >10.4172/2329-6917.S1-001</a>

Result language
angličtina
Original language name
Prognostic Scoring Systems in CML - Improvement Impossible?
Original language description
Since introduction of oral chemotherapy in the treatment of CML there is a continual effort for estimation of prognosis including future response to the therapy. Despite the first efficient prognostic scoring systems were designed for the patients treated with busulfan or hydroxyurea and interferon-alpha, respectively, Sokal and Hasford (Euro) scores are used for the patients treated with tyrosine kinase inhibitors (TKI) nowadays with a very good predictive value. The EUTOS score - specifically designedfor the treatment with TKI - is (unlikely the previous scores) very easy to be counted, however, in some cohorts of patients failed to provide optimal predictive role for overall survival of patients. New strategies for CML prognostic score computationinclude implementation of newly designed statistic tools and end-points. On the other hand there is a simple possibility of designing the combination scores or including the early response to the treatment into the scoring system. However
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—

Publication year
2015
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)